Generic Name and Formulations:
Letrozole 2.5mg; tabs.
Novartis Pharmaceuticals Corp
Indications for FEMARA:
In postmenopausal women: Adjuvant treatment of hormone receptor positive early breast cancer; Extended adjuvant treatment of early breast cancer after 5 years of adjuvant tamoxifen therapy; First-line treatment of hormone receptor positive or unknown, locally advanced or metastatic breast cancer; Treatment of advanced breast cancer with disease progression following antiestrogen therapy.
2.5mg once daily. Adjuvant or extended adjuvant therapy: discontinue at tumor relapse; see full labeling. Advanced breast cancer: continue until tumor progression is evident. Severe hepatic impairment or cirrhosis: 2.5mg every other day.
Monitor bone mineral density, serum cholesterol. Severe renal or hepatic impairment. Embryo-fetal toxicity; exclude pregnancy prior to initiation. Use effective contraception during and for ≥3wks after last dose. Nursing mothers: not recommended (during and for ≥3wks after last dose).
Pain (bone, musculoskeletal, and others), hot flashes, arthralgia, flushing, asthenia, edema, headache, dizziness, hypercholesterolemia, sweating increased, GI upset, fatigue, somnolence, dyspnea, cough, insomnia, hypertension, anorexia, weight changes; thromboembolic or cardio- or cerebrovascular events (rare).
Sign Up for Free e-newsletters
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- A Witness to Letting Go: Nursing Care at the End of Life
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Modified XELIRI Noninferior to FOLFIRI for OS in Metastatic Colorectal Cancer
- Nabilone Improves Cancer-Associated Anorexia in Lung Cancer
- Direct-to-Consumer Genetic Test for Select BRCA Mutations Gets FDA Nod
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|